Balance Sheet Details (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
|---|
| Disclosure Text Block Supplement [Abstract] |
|
| Schedule of Inventories |
Inventories primarily relate to ENTADFI® product and consisted of the following as of December 31, 2023 and 2022:
|
|
|
December 31,
2023
|
|
December 31,
2022
|
|
Raw materials
|
|
$
|
139,208 |
|
$
|
|
|
Work-in-process
|
|
|
194,805 |
|
|
|
|
Finished goods
|
|
|
30,039 |
|
|
|
|
Total
|
|
$
|
364,052 |
|
$
|
|
|
| Schedule of Prepaid Expenses and Other Current Assets |
Prepaid expenses and other current assets consisted of the following as of December 31, 2023 and 2022:
|
|
|
December 31,
2023
|
|
December 31,
2022
|
|
Prepaid insurance
|
|
$
|
122,004 |
|
$
|
148,789 |
|
Prepaid regulatory fees
|
|
|
312,551 |
|
|
|
|
Prepaid research and development
|
|
|
89,195 |
|
|
231,981 |
|
Prepaid professional fees
|
|
|
70,708 |
|
|
|
|
Prepaid other
|
|
|
175,695 |
|
|
88,462 |
|
Total
|
|
$
|
770,153 |
|
$
|
469,232 |
|
| Schedule of Intangible Assets |
Intangible assets, which were recorded during the year ended December 31, 2023 in connection with the ENTADFI and Proteomedix acquisitions (see Note 5), is comprised of customer relationships, product rights for developed technology, and a trade name, and consisted of the following as of December 31, 2023:
|
|
|
Cost
|
|
Impairment
|
|
Effect of
Currency
Translation
|
|
Balance
|
|
Cost basis:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade name
|
|
$
|
9,018,000 |
|
$
|
|
|
|
$
|
294,739 |
|
$
|
9,312,739 |
|
Product rights for developed technology
|
|
|
28,447,771 |
|
|
(14,610,128 |
)
|
|
|
344,514 |
|
|
14,182,157 |
|
Customer relationships
|
|
|
1,891,000 |
|
|
|
|
|
|
61,803 |
|
|
1,952,803 |
|
Total
|
|
$
|
39,356,771 |
|
$
|
(14,610,128 |
)
|
|
$
|
701,056 |
|
$
|
25,447,699 |
|
|
|
Amortization
|
|
Balance
|
|
Accumulated amortization:
|
|
|
|
|
|
|
|
|
|
Trade name
|
|
$
|
|
|
|
$
|
|
|
|
Product rights for developed technology
|
|
|
(31,213 |
)
|
|
|
(31,213 |
)
|
|
Customer relationships
|
|
|
(5,599 |
)
|
|
|
(5,599 |
)
|
|
Total
|
|
$
|
(36,812 |
)
|
|
$
|
(36,812 |
)
|
|
Intangible assets, net
|
|
|
|
|
|
$
|
25,410,887 |
|
|
| Schedule of Annual Amortization Expense |
Future annual amortization expense related to the Company’s finite lived intangible assets is as follows as of December 31, 2023:
|
Years ending December 31,
|
|
|
|
|
2024
|
|
$
|
1,012,870 |
|
2025
|
|
|
1,326,837 |
|
2026
|
|
|
1,326,837 |
|
2027
|
|
|
1,326,837 |
|
2028
|
|
|
1,326,837 |
|
Thereafter
|
|
|
9,777,930 |
|
Total
|
|
$
|
16,098,148 |
|
| Schedule of Goodwill |
Goodwill was recorded during the year ended December 31, 2023, in connection with the Proteomedix acquisition (see Note 5), and consisted of the following as of December 31, 2023:
|
|
|
December 31,
2023
|
|
Balance as of December 31, 2022
|
|
$
|
|
|
PMX Transaction goodwill
|
|
|
53,914,055 |
|
Effect of currency translation
|
|
|
1,762,087 |
|
Balance as of December 31, 2023
|
|
$
|
55,676,142 |
|
| Schedule of Accrued Expenses |
Accrued expenses consisted of the following as of December 31, 2023 and 2022:
|
|
|
December 31,
2023
|
|
December 31,
2022
|
|
Accrued research and development
|
|
$
|
616,707 |
|
$
|
847,747 |
|
Accrued compensation
|
|
|
487,579 |
|
|
1,132,859 |
|
Accrued deferred offering costs
|
|
|
125,000 |
|
|
125,000 |
|
Accrued professional fees
|
|
|
550,415 |
|
|
|
|
Accrued implementation fees
|
|
|
93,787 |
|
|
|
|
Other accrued expenses
|
|
|
265,849 |
|
|
125,922 |
|
Accrued franchise taxes
|
|
|
60,530 |
|
|
177,600 |
|
Total
|
|
$
|
2,199,867 |
|
$
|
2,409,128 |
|